Since CIP2A overexpression has been previously involved in doxorubicin resistance, and since AKT represents a CIP2A downstream effector, we hypothesized that upregulation of p-AKT could play a relevant role determining doxorubicin response in breast cancer patients. This evidence concerns the gene CIP2A and breast cancer.